Abstract
A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding
Author(s): Rush Steven D, Vernak Charlene, Zhao Fang
Issue: Jan/Feb 2017 - Volume 21, Number 1
Page(s): 83-87
Abstract
Dehydroepiandrosterone supplementation is used to treat a variety of conditions. Rapid-dissolving tablets are a relatively novel choice for compounded dehydroepiandrosterone dosage forms. While rapid-dissolving tablets offer ease of administration, there are uncertainties about the physical and chemical stability of the drug and dosage form during preparation and over long-term storage. This study was designed to evaluate the stability of dehydroepiandrosterone rapid-dissolving tablets just after preparation and over six months of storage. The Professional Compounding Centers of America rapid-dissolving tablet mold and base formula were used to prepare 10-mg strength dehydroepiandrosterone rapid-dissolving tablets. The formulation was heated at 100°C to 110°C for 30 minutes, released from the mold, and cooled at room temperature for 30 minutes. The resulting rapid-dissolving tablets were individually packaged in amber blister packs and stored in a stability chamber maintained at 25°C and 60% relative humidity. The stability samples were pulled at pre-determined time points for evaluation, which included visual inspection, tablet weight check, United States Pharmacopeia disintegration test, and stability-indicating high-performance liquid chromatography. The freshly prepared dehydroepiandrosterone rapiddissolving tablets exhibited satisfactory chemical and physical stability. Time 0 samples disintegrated within 40 seconds in water kept at 37°C. The high-performance liquid chromatographic results confirmed that the initial potency was 101.9% of label claim and that there was no chemical degradation from the heating procedure. Over six months of storage, there were no significant changes in visual appearance, physical integrity, or disintegration time for any of the stability samples. The high-performance liquid chromatographic results also indicated that dehydroepiandrosterone rapid-dissolving tablets retained >95% label claim with no detectable degradation products. The dehydroepiandrosterone rapid-dissolving tablets investigated in this pilot study were physically and chemically stable during preparation and over six months of storage at 25°C and 60% relative humidity.
Related Keywords
- dehydroepiandrosterone
- DHEA
- rapid-dissolving tablets
- hormone
- steroid
- neurosteroid
- sexual dysfunction
- cognitive decline
- osteoporosis
- infertility
- formulation
- stability
Related Categories
- FORMULATIONS
- PEER-REVIEWED
- STABILITIES, COMPATIBILITIES
- DOSAGE FORMS/DRUG CARRIERS
- ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
- STORAGE
Related Articles from IJPC
Issue/Page View/Buy |
Title/Author (Click for Abstract / Details / Purchase) |
---|---|
Jan/Feb 2017
Pg. 83-87
|
|
Jan/Feb 2021
Pg. 82-87
|
|
Jan/Feb 2019
Pg. 62-64
|
|
Nov/Dec 2003
Pg. 449-450
|
Author(s):
Allen Loyd V Jr
|
May/Jun 2003
Pg. 233-239
|
|
Mar/Apr 2005
Pg. 151
|
Author(s):
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 465-471
|
Author(s):
Bramwell Bethany L
|
Jul/Aug 2020
Pg. 299-303
|
Author(s):
Taylor Andrew
|
Sep/Oct 2003
Pg. 389-393
|
Author(s):
Alexander Kenneth S, Thyangarajapuram N
|
Sep/Oct 2001
Pg. 381
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2024
Pg. 65
|
Author(s):
Allen Loyd V Jr
|
Nov/Dec 2011
Pg. 521-525
|
Author(s):
Jha Antesh Kr, Chetia D
|
Jan/Feb 2015
Pg. 6-12
|
|
Jan/Feb 2016
Pg. 49
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 148-155
|
|
Sep/Oct 2022
Pg. 370-377
|
Author(s):
Ejeta Fikadu
|
Mar/Apr 2022
Pg. 163-174
|
|
May/Jun 2023
Pg. 240-249
|
|
May/Jun 2004
Pg. 181-185
|
Author(s):
Hinkle Amanda R, Newton Gail D
|
May/Jun 2022
Pg. 255-263
|